Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

AskMen.com	Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good.
Science News May 13, 2000	Cancer Net CancerNet is a huge compendium of information on cancer assembled by the National Cancer Institute....
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
Chemistry World September 28, 2012 Andrew Turley	Regorafenib approved in US US authorities have approved Stivarga (regorafenib) tablets for the treatment of advanced colorectal cancer.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool June 28, 2007 Brian Orelli	Onyx's Hard at Work Onyx's future depends on getting Nexevar approved for new indications. The liver cancer expansion is a nice start, and it should bring Onyx into the black. Investors, take note.
American Family Physician February 15, 2005	Health Care After Cancer Treatment An informative patient hand-out on follow-up cancer care.
The Motley Fool December 27, 2006 Brian Lawler	Telik Falls Short Shares of another biopharma fall after disappointing clinical trial results.
The Motley Fool June 12, 2007 Brian Lawler	ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label.
American Family Physician December 15, 2002 Randhawa & Fink	Screening for Breast Cancer A case study and question-and-answer group on screening for breast cancer, based on the recommendations of the current U.S. Preventive Services Task Force
The Motley Fool August 8, 2007 Brian Orelli	Onyx Is Almost There Onyx Pharmaceutical narrowed losses for the quarter, and things should improve even more in the months to come, even as their bottom line is still being hampered by endless clinical trials.
Science News May 19, 2007	Science Safari: Cancer Risk -- Understanding the Puzzle This new Web site from the National Cancer Institute cuts through the hype to help you understand the plain and simple truth about cancer risk.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
The Motley Fool November 20, 2007 Brian Orelli	Explaining Onyx Pharmaceuticals' Sell-Off The FDA approved Nexavar as a treatment for liver cancer, but the good news causes a sell-off of the stock.
The Motley Fool February 13, 2007 Brian Lawler	Rock-Solid News From Onyx Results show that the drug Nexavar works in another type of cancer. But investors need to consider other issues when taking a closer look at this pharma.
American Family Physician February 1, 2001 Thomas J. Gates	Screening for Cancer: Evaluating the Evidence This article reviews the kind of evidence required to justify screening tests for cancer, with the goal of guiding family physicians through current and future screening controversies...
Managed Care January 2005 Sharon Baker	Breast Cancer Screening: Some Plans Do Better Than Others Some of the nation's best health plans are coming up with creative ways to encourage women to get mammograms.
Chemistry World September 2, 2014 Phillip Broadwith	Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer.
The Motley Fool June 17, 2010 Luke Timmerman	Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials.
The Motley Fool May 7, 2008 Brian Orelli	Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year.
Managed Care January 2007 Lola Butcher	Employers Publish Guide on Prevention's Worth The National Business Group on Health introduces the Purchaser's Guide to Clinical Preventive Services
The Motley Fool April 27, 2007 Mike Havrilla	Detecting an Opportunity in EXACT Sciences Thanks to a strong balance sheet and low burn rate, shares of EXACT are poised to go up in the next few months.
The Motley Fool June 2, 2009 Brian Orelli	Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool May 4, 2009 Robert Steyer	Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success?
The Motley Fool August 27, 2007 Brian Orelli	Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up.
American Family Physician March 15, 2001	Cancer Screening Guidelines Faced with the broad, and sometimes conflicting, range of recommendations for cancer screening, family physicians must determine the most reasonable and up-to-date method of screening...
Nurse Practitioner December 2008 Darlene P. Peters	Colon Cancer Screening: Recommendations and Barriers to Patient Participation Advanced practice nurses and nurse researchers can play a vital role in improving colon cancer screening among patients.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool September 28, 2010 Brian Orelli	Pfizer's Sutent Fails. Again! No surprise here.
Managed Care May 2001	3rd U.S. Preventive Task Force Issues Recommendations The Third U.S. Preventive Services Task Force released its first of 70 sets of recommendations about the value of specific preventive services...
Fast Company July 1, 2007 Tinker Ready	Can CEOs Cure Cancer? Big Pharma execs may not know more about the disease than the rest of us, but a group of them are using their power to fight it.
The Motley Fool December 20, 2004 Charly Travers	More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.
The Motley Fool April 12, 2005 Brian Gorman	Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently.
The Motley Fool April 3, 2009 Brian Orelli	Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
BusinessWeek July 17, 2006 Bruce Einhorn	A Key New Ally In The Cancer War China and its Western trade partners are fighting together on at least one front: the war on cancer.
The Motley Fool December 5, 2006 Brian Lawler	Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder.
The Motley Fool July 16, 2007 Brian Lawler	Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.
Managed Care March 2007 Lola Butcher	Plans Put Greater Emphasis On Cancer Management Increasingly, health plans are rolling out services designed to help cancer patients and, before that, plan members at a high risk of cancer, to improve their health care and, in doing so, limit costs.
The Motley Fool February 24, 2004 David Nierengarten	Cell Genesys Boosted Cell Genesys's shares jump a day late and a dollar higher.
AskMen.com Jacob Franek	Prostate Cancer Symptoms, Screening & Diagnosis Despite the facts that prostate cancer is the No. 1 cancer occurring in men (aside from skin cancers) and the second leading cause of cancer death (behind lung cancer), many men are still unfamiliar with this highly treatable disease.
Scientific American November 2008 Jessica Wapner	Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation
The Motley Fool May 29, 2007 Brian Lawler	Amgen Is Vexed The European Union medical authority says no to Amgen's cancer compound. Investors, take note.
Pharmaceutical Executive February 1, 2013 William Looney	In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer.
American Family Physician May 15, 2005	Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options.